LAS VEGAS, Oct. 15 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord bloodstem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells, a biological insurance policy for families nationwide and internationally, today addressed shareholder questions
The entire interview is available at http://gaskinsco.com/cbai-10-14-09.mp3
In the interview Mr. Schissler said:
The interview also includes details about the Company’s future business strategies and possible business opportunities, which are being evaluated. Mr. Schissler said the new facility will significantly reduce storage costs for Cord Blood America and will allow it to do research and development and to process and store multiple stem cell lines or other medical products.
About Cord Blood America
Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.
Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as ``anticipate,'' ``believe,'' ``expect,'' ``future,'' ``intend,'' ``plan,'' and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company’s performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
SOURCE Cord Blood America, Inc.
Subscribe to our Free Newsletters!
Adult immunization is needed for adults whose mandatory childhood vaccines were either missed out ...
Snake antivenom is a medicine used for the treatment of patients suffering from snake envenomation.
Breast Cancer Risk Assessment Calculator predicts the risk for breast cancer. Find list of breast ...View All